e-therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

e-therapeutics şirketinin toplam hissedar öz sermayesi £27.5M ve toplam borcu £0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla £28.8M ve £1.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

UK£0

Borç

Faiz karşılama oranı	n/a
Nakit	UK£24.85m
Eşitlik	UK£27.53m
Toplam yükümlülükler	UK£1.28m
Toplam varlıklar	UK£28.81m

Son finansal sağlık güncellemeleri

Recent updates

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Jan 05

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Sep 13

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Mar 27

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Jul 07

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Oct 28

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

Mar 21

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Feb 14

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

Jan 10

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

Dec 06

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ETX 'nin kısa vadeli varlıkları ( £28.3M ) kısa vadeli yükümlülüklerini ( £1.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: ETX un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ETX borçsuzdur.

Borcun Azaltılması: ETX son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ETX şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: ETX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

e-therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

e-therapeutics plc Considers Switching Its Listing to New York

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United States

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

Recent updates

e-therapeutics plc Considers Switching Its Listing to New York

e-therapeutics plc, Annual General Meeting, Apr 29, 2024

New minor risk - Market cap size

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

e-therapeutics Ordinary Shares to Cease to Trade on the OTCQX Best Market in the United States

New minor risk - Share price stability

e-therapeutics plc to Report First Half, 2024 Results on Oct 26, 2023

E-Therapeutics plc Announces Senior Management Update

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics plc, Annual General Meeting, Jul 18, 2023

Full year 2023 earnings released: UK£0.015 loss per share (vs UK£0.017 loss in FY 2022)

e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans

Less than half of directors are independent

First half 2023 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in 1H 2022)

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

e-therapeutics plc, Annual General Meeting, Jul 19, 2022

Full year 2022 earnings released: UK£0.016 loss per share (vs UK£0.01 loss in FY 2021)

Less than half of directors are independent

First half 2022 earnings released: UK£0.005 loss per share (vs UK£0.006 loss in 1H 2021)

CEO & Director recently bought UK£100k worth of stock

We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn

Full year 2021 earnings released: UK£0.01 loss per share (vs UK£0.009 loss in FY 2020)

e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £22.5 million.

Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?

e-Therapeutics plc Announces Board Changes

We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth

New 90-day high: UK£0.22

e-Therapeutics plc Announces Addition of its RNAi Platform as a Therapeutic Drug Modality

Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?

New 90-day high: UK£0.21

e-therapeutics plc Announces Results of Experimental Testing on the Compounds for the Treatment of Covid-19 Identified Using Its Proprietary Network-Driven Drug Discovery (Ndd) Platform

Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?

First half earnings released

e-therapeutics plc Announces Appointment of Ali Mortazavi as CEO

e-therapeutics plc to Report First Half, 2020 Results on Oct 12, 2020

e-therapeutics plc Announces Executive Changes

e-therapeutics plc has completed a Follow-on Equity Offering in the amount of £0.75 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin